|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CAR is found in normal epithelial cells and is increased in abundance in various human tumors, including lung carcinomas.
|
29382784 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CAR T cell therapy has shown stunning results especially in B-cell malignancies; however, it has shown less success against solid tumors, which is more supposed to be related to the specific characteristics of the tumor microenvironment.
|
30108584 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CAR T cells lacking all three NR4A transcription factors (Nr4a triple knockout) promoted tumour regression and prolonged the survival of tumour-bearing mice.
|
30814732 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CAR is involved in the formation of epithelial tight junctions and promotes tumor growth in some cancers.
|
31512325 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A homologous, all murine anti-CD70 CAR model was also used to assess treatment-related toxicities.<b>Results:</b> The CAR consisting of the extracellular binding portion of CD27 fused with 41BB and CD3-zeta (trCD27-41BB-zeta) conferred the highest IFNγ production against CD70-expressing tumors <i>in vitro</i>, and NSG mice bearing established CD70-expressing human tumors could be cured by human lymphocytes transduced with this CAR.
|
27803044 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Ad-mTNFa-mIL2 increased both CAR T cell and host T cell infiltration to the tumor and altered host tumor immune status with M1 polarization of macrophages and increased dendritic cell maturation.
|
29618658 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Additionally, the CAR-T cells inhibited growth of cell-line- and patient-derived xenograft TNBC tumors in mice.
|
31804974 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Adoptive T cell therapy (ACT) is a safe and effective personalized cancer immunotherapy that can comprise naturally occurring ex vivo expanded cells (e.g., tumor-infiltrating lymphocytes [TIL]) or T cells genetically engineered to confer antigen specificity (T-cell receptor [TCR] or chimeric antigen receptor [CAR] engineered T cells) to mediate cancer rejection.
|
30649750 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Adoptive T cell transfer therapy (ACT) using tumor infiltrating lymphocytes or lymphocytes redirected with antigen receptors (CAR or TCR) has revolutionized the field of cancer immunotherapy.
|
30842774 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Adoptive transfer of a patient's own T cells, genetically modified ex vivo through the introduction of a gene encoding a chimeric antigen receptor (CAR) targeted to a tumor-associated antigen, is a novel approach to the treatment of ovarian cancer.
|
20628030 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Adoptive transfer of T lymphocytes expressing a CD19-specific chimeric antigen receptor (CAR.CD19) induces complete tumor regression in patients with lymphoid malignancies.
|
24782509 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Advancing the use of adoptively transferred T cells for the treatment of patients with solid tumor and other hematologic malignancies however, will require addressing numerous effector cell intrinsic as well as tumor micro environmental hurdles and exploiting a broader ACT platform that includes not only engineered CAR-T cells, but also other forms of ACT including Endogenous T Cell (ETC) and Tumor-infiltrating Lymphocyte (TIL) therapy.
|
29730057 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Autologous CAR T cells are generated from the patient's peripheral blood T cells and expand in the recipient to eliminate the targeted tumor.
|
29245005 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Based on these studies, it was demonstrated that the liver tumors were mediated by a mode of action (MoA) involving nuclear receptors (NRs) through the following key events: (1) CAR and PPAR-α receptor activation, (2) increased hepatocellular proliferation, eventually leading to (3) hepatocellular tumors.
|
25092647 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Because CAR-T cells recognize tumor cells independent of their expression of human leukocyte antigen (HLA) molecules, tumors that escape conventional T cells by downregulating HLA and/or mutating components of the antigen processing machinery can be eliminated.
|
25621840 |
2015 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
BiTEs were secreted from the transferred T cells and enabled both the transferred and bystander T cells to specifically recognize CD19(+) cell lines, with increased tumor killing ability, prolonged functional persistence, increased cytokine production and potent proliferation compared with the CAR-T cells.
|
27258611 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
By comparison, the CD4+ CAR T cells persisted after tumor challenge and sustained their effector potency.
|
29769444 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CAR T cells bearing a functional chemokine receptor can overcome the inadequate tumor localization that limits conventional CAR targeting strategies and can significantly improve antitumor efficacy in vivo.
|
21610146 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Chimeric antigen receptor T (CAR-T) cell therapy has achieved unprecedented success among hematologic tumors, but its role in treating solid tumors is still unclear.
|
30886654 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Collectively, our results indicate that TRIM13 behaves as a tumor suppressor in NSCLC through regulating NF-κB pathway.
|
31357025 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Evaluating CAR-T Cell Therapy in a Hypoxic 3D Tumor Model.
|
30734529 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Even though hundreds of clinical trials are undergoing exploring a variety of tumor-associated antigens (TAA), no such antigen with comparable properties like CD19 has yet been identified regarding solid tumors CAR-T immunotherapy.
|
29433552 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Extending the use of CAR therapies to cancers other than B-cell malignancies will require selective tumor targeting with minimal or acceptable "on-target, off-tumor" effects.
|
24667964 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, lack of response to CAR T cell treatment is due in some cases to intrinsic autologous T cell defects and/or the inability of these cells to function optimally in a strongly immunosuppressive tumor microenvironment.
|
30735463 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, our data suggested that AMG102 treatment alone might increase leukocyte infiltration including efficient CAR-T access into tumor mass and thereby improves its antitumor activity.
|
31621900 |
2019 |